


Image

1631/9

Attorney's Docket No. 9052-111

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Antson et al.
Serial No.: 10/088,245
Filed: July 3, 2002
For: TARGET FOR ANTIVIRAL THERAPY

Examiner: Cheyne D. Ly
Group Art Unit: 1631
Confirmation No. 9401

Date: March 11, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Applicants have received and reviewed the Restriction Requirement dated January 29, 2004.

REMARKS

In response to the Restriction Requirement dated January 29, 2004, set forth therein, Applicants hereby elect Group I, Claims 11-9, 27 and 28 "drawn to a crystal of molecular complex of E2NT", with traverse, for substantive examination.

Applicants respectfully request reconsideration of the restriction requirement as to Groups II - III. It is respectfully submitted that a search of these claims would overlap with a search of Group I because they are listed in the same class 702 and subclass 270. Grouping these claims together would not present an undue burden to the Patent Office in examining the patent application.

A Petition for an Extension of Time with appropriate fees accompanies this response. The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.